Clinical trial · Observational
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).
NCT06909253CI-TRIAL-00122097MG-ARCADIArecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260917-000001
Summary
Brief summary (as posted)
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis, Generalized | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ravulizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ravulizumab
- description
- Open-lable arm with gMG patients who received ravulizumab treatment in the frames of NDP in Poland.
- interventionNames
- Drug: Ravulizumab
Primary outcomes (1)
- measure
- Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score
- timeFrame
- at 6 month
Secondary outcomes (9)
- measure
- Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score
- timeFrame
- at month 12, 24, 36
- measure
- Change from baseline in MG-ADL subcomponent scores
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland. * Patients willing to participate in the study and signed Informed Consent Form (ICF). * Vaccination against N. meningitidis Exclusion Criteria: * Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP. * Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
References
Publications (0)
Data not yet available
No reference posted for this study.